Sugi Predict

Sugi Predict / Compounds / Butenafine

Butenafine

Butenafine

SCHEMBL500751

CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12.NCc1ccccc1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 4/20 0.85
▸ LMNA P02545 4/20 0.85
▸ SIGMAR1 Q99720 4/20 0.85
▸ SLC6A2 P23975 3/20 0.85
▸ NR1I2 O75469 2/20 0.85
▸ HTR2A P28223 2/20 0.85
▸ SLC6A4 P31645 2/20 0.85
▸ KCNH2 Q12809 2/20 0.85
▸ ADRA2A P08913 2/20 0.85
▸ ACHE P22303 1/20 0.85
▸ CYP1A2 P05177 2/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ CYP19A1 P11511 1/20 0.52
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ DRD2 P14416 1/20 0.45
▸ ADRA2C P18825 1/20 0.45
▸ CNR1 P21554 1/20 0.45
▸ ADRA1A P35348 1/20 0.45
▸ OPRK1 P41145 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butenafine SCHEMBL65526 0.92 CYP2D6 (1.00) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL20456391 0.92 CYP2D6 (1.00) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL29354083 0.92 CYP2D6 (1.00) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL29459249 0.91 LMNA (0.97) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL262301 0.91 LMNA (0.97) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL676912 0.91 LMNA (0.97) CYP2D6LMNASIGMAR1SLC6A2NR1I2
Butenafine SCHEMBL1648813 0.90 CYP2D6 (0.94) CYP2D6LMNASIGMAR1SLC6A2NR1I2
SCHEMBL9695182 0.84 CYP2D6 (0.80) CYP2D6LMNASIGMAR1SLC6A2NR1I2
SCHEMBL9722032 0.82 CYP2D6 (0.75) CYP2D6LMNASIGMAR1SLC6A2NR1I2
SCHEMBL9312678 0.81 CYP2D6 (0.78) CYP2D6LMNASIGMAR1SLC6A2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112888443-A Injectable composition with prolonged duration of action for its use in the treatment of nail diseases and/or for accelerating nail growth 爱迪克斯-欧有限公司 2021-06-01 — — CN disclosed
US-20210154215-A1 Antifungal Cuticle Oil Composition ZENVISION PHARMA LLP (IN) 2021-05-27 — — US disclosed
EP-3424932-B1 BORONOPHTHALIDES FOR THERAPEUTIC USE ANACOR PHARMACEUTICALS INC (US) 2021-04-07 — — EP disclosed
US-20210070780-A1 Boron-Containing Small Molecules ANACOR PHARMACEUTICALS, INC. (US) 2021-03-11 — — US disclosed
US-20190330245-A1 Boron-Containing Small Molecules ANACOR PHARMACEUTICALS, INC. (US) 2019-10-31 — — US disclosed
US-20190048026-A1 Boron-Containing Small Molecules ANACOR PHARMACEUTICALS, INC. (US) 2019-02-14 — — US disclosed
EP-3424932-A1 BORONOPHTHALIDES FOR THERAPEUTIC USE Anacor Pharmaceuticals, Inc (US) 2019-01-09 — — EP disclosed
EP-2987796-B1 HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS ANACOR PHARMACEUTICALS INC (US) 2018-08-08 — — EP disclosed
US-20180016285-A1 Boron-Containing Small Molecules ANACOR PHARMACEUTICALS, LLC 2018-01-18 — — US disclosed
EP-2164331-B1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS INC (US) 2017-11-29 — — EP disclosed
WO-2006089067-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2006-08-24 — — WO disclosed
EP-1648556-A1 METHOD, APPARATUS, AND KIT FOR ONYCHOMYCOSIS TREATMENT USING ELECTROKINETIC TRANSPORT OF SUBSTANCES Power Paper Ltd. (IL) 2006-04-26 — — EP disclosed
US-20050038375-A1 Method, apparatus, and kit for onychomycosis treatment POWER PAPER LTD. (IN LIQUIDATION) (IL) 2005-02-17 — — US disclosed
WO-2005004980-A1 METHOD, APPARATUS, AND KIT FOR ONYCHOMYCOSIS TREATMENT USING ELECTROKINETIC TRANSPORT OF SUBSTANCES POWER PAPER LTD. (IL) 2005-01-20 — — WO disclosed
EP-1071413-B1 TOPICAL FORMULATIONS FOR THE TREATMENT OF NAIL FUNGAL DISEASES BERTEK PHARM INC (US) 2004-06-16 — — EP disclosed
US-20040062733-A1 Subunguicide, and method for treating onychomycosis HALLUX, INC. 2004-04-01 — — US disclosed
EP-1071413-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF NAIL FUNGAL DISEASES Bertek Pharmaceuticals, Inc. (US) 2001-01-31 — — EP disclosed
US-6143794-A AMINE FUNGICIDES FOR NAILS BERTEK PHARMACEUTICALS, INC. (US) 2000-11-07 — — US disclosed
US-6075056-A FOR FUNGI-CAUSED SKIN DISORDERS PENEDERM, INC. (US) 2000-06-13 — — US disclosed
WO-1999053913-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF NAIL FUNGAL DISEASES BERTEK PHARMACEUTICALS, INC. (US) 1999-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330245-A1 Boron-Containing Small Molecules ETF1, POLR1C, DPM1 CYP2D6 1080/4885LMNA 3138/4885SIGMAR1 4116/4885
US-20210154215-A1 Antifungal Cuticle Oil Composition NACA, POLR1C, CUTA CYP2D6 1634/4885LMNA 3537/4885SIGMAR1 762/4885
US-20210070780-A1 Boron-Containing Small Molecules ETF1, POLR1C, DPM1 CYP2D6 1080/4885LMNA 3138/4885SIGMAR1 4116/4885
US-20180016285-A1 Boron-Containing Small Molecules BCL6B, BLVRB, BCL6 CYP2D6 4367/4885LMNA 4338/4885SIGMAR1 2325/4885
US-20190048026-A1 Boron-Containing Small Molecules ETF1, POLR1C, DPM1 CYP2D6 1080/4885LMNA 3138/4885SIGMAR1 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.